# Gestalt Diagnostics

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/gestalt-diagnostics

- Industry: Software
- Headquarters: Spokane, US
- Website: www.gestaltdiagnostics.com
- Total disclosed funding: $7.5M
- Latest round: Series A (Apr 28, 2025)
- Investors on record: 5

## About

Gestalt Diagnostics specializes in advanced digital pathology solutions, enhancing laboratory workflows and improving diagnostic accuracy through its innovative software platform, PathFlow®.Gestalt Diagnostics, founded in 2017 in Spokane, US, provides digital pathology solutions that streamline laboratory processes. The company has successfully completed 2 deals, with its most recent being a Series A funding round on April 28, 2025, where it raised USD 7.5 mn from investors including Cowles Company, Inland Imaging, Kickstart Capital, and TechVision Fonds. The founder's history is not publicly documented, nor are there mentions of prior companies founded by them.Gestalt specializes in advanced digital pathology solutions that enhance the workflow of pathology laboratories. Their flagship product, PathFlow®, is a sophisticated software platform that integrates with existing laboratory information systems (LIS) to provide a streamlined, fully interoperable workflow. This solution accommodates the needs of a diverse client base, including health systems, laboratories, and hospitals, by improving the speed and accuracy of disease diagnosis. PathFlow® leverages a widely adopted radiology workflow engine that supports over 13 million reads per year, facilitating efficient case management across multiple locations. The company's services encompass installation, implementation, training, and ongoing support, ensuring that clients can maximize the capabilities of their digital pathology systems. Gestalt operates in various geographical markets, including the United States and the European Union, where its products are CE-IVD marked for compliance.Gestalt generates revenue primarily through subscriptions and service agreements associated with its digital pathology solutions, including the PathFlow® product. Business transactions typically involve health systems, laboratories, and hospitals entering into contracts for software licenses and support services. Clients pay for the implementation of the PathFlow® system, which includes a comprehensive onboarding process, followed by ongoing service fees for maintenance and support. The company’s revenue model is structured around providing tailored solutions and services that address specific workflow needs within the pathology sector. By focusing on the integration of innovative technology and customer support, Gestalt positions itself strategically within the healthcare IT landscape, enhancing its value proposition to clients.In April 2025, Gestalt Diagnostics raised USD 7.5 mn in Series A funding, co-led by Cowles Company, Inland Imaging, Kickstart Capital, TechVision Fonds, and individual investors. The company plans to utilize the funding to expand its customer base, enhance artificial intelligence capabilities, and pursue regulatory clearance from the U.S. Food and Drug Administration for its digital pathology platform. Gestalt aims to launch new products designed to integrate advanced AI functionalities, targeting new markets in North America and Europe by the end of 2026.

## Funding rounds

- Series A, Apr 28, 2025, $7.5M — Kickstart, McKesson Ventures, Cowles Company, TechVision Fonds, Inland Imaging

## Investors

- Kickstart (https://capitalatlas.ai/funds/kickstart) — Series A
- McKesson Ventures (https://capitalatlas.ai/funds/mckesson-ventures) — Series A
- Cowles Company (https://capitalatlas.ai/funds/cowles-company) — Series A
- TechVision Fonds (https://capitalatlas.ai/funds/techvision-fonds) — Series A
- Inland Imaging — Series A